• EZ Cap™ Firefly Luciferase mRNA: Evidence Overview

  2026-10-04

  This source-grounded overview explains how EZ Cap™ Firefly Luciferase mRNA can function as a transient reporter for delivery, translation, and gene-regulation research. It also distinguishes supplier-reported product attributes from findings in a 2025 nanoparticle-delivered Dsup mRNA study, whose radioprotection results should not be interpreted as evidence for luciferase mRNA or for clinical use.

• Angiotensin I/II (1-5): Product Overview

  2026-10-03

  APExBIO lists Angiotensin I/II (1-5), SKU A1047, as an Asp-Arg-Val-Tyr-Ile peptide fragment associated with renin-angiotensin system research. No matched paper evidence was provided, so its reported biological context and product attributes remain supplier-documented rather than independently validated.

• TaqI Restriction Endonuclease Protocol Guide

  2026-10-02

  TaqI Restriction Endonuclease (SKU K3053) provides sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA at the TCGA recognition site, with a stated digestion time of 5–15 minutes. It is intended for research workflows such as mapping, cloning, and gel analysis, not diagnostic or medical use.

• Cationic Lipid Design Shapes mRNA Vaccine Responses

  2026-10-01

  The reference study systematically compared cationic and neutral lipid combinations in mRNA lipoplexes prepared by a modified ethanol injection method. Lipoplexes containing DC-1-16 or DDAB with DOPE and PEG-Chol produced strong anti-OVA IgG1 responses and high luciferase expression in the lungs and spleen, highlighting carrier composition as a major determinant of systemic mRNA performance.

• WST-8 Glucose Uptake Assay: Practical Guide

  2026-10-01

  Learn how to turn 2-DG transport and phosphorylation into a reliable 450 nm readout for insulin-response, cancer metabolism, and nucleic-acid delivery studies. This guide combines assay workflow design with ion-aware controls inspired by recent CPP formulation research.

• HyperScript™ First-Strand cDNA Kit for Colitis

  2026-09-30

  The HyperScript First-Strand cDNA Synthesis Kit supports sensitive RNA analysis in colitis models. This article connects CeO2 nanomedicine findings with practical reverse-transcription decisions for PCR amplification, qPCR reaction design, and pathway interpretation.

• GLI2–PRDX1 Axis Drives Ferroptosis Resistance

  2026-09-30

  A 2026 study identifies GLI2 as a transcriptional driver of PRDX1 expression and ferroptosis resistance in bladder cancer. Its combination of public-data analysis, GLI2 perturbation, RNA sequencing, ChIP, and rescue experiments connects Hedgehog pathway signaling to cisplatin response and suggests a mechanistically testable therapeutic axis.

• Imipenem Workflows for Antibacterial Research

  2026-09-29

  Imipenem supports more than routine susceptibility testing: it can connect antibacterial assays, immune response modulation, and controlled-release implant studies. This practical guide translates a spatial proteomics platform into reproducible workflows while separating product-backed evidence from research recommendations.

• ARCA: Engineering Better mRNA Translation

  2026-09-29

  A mechanistic and translational guide to Anti Reverse Cap Analog (ARCA), showing how orientation-controlled capping can strengthen synthetic mRNA workflows for reprogramming, gene expression, and mRNA therapeutics research.

• GW 6471: Strategic PPARα Antagonism for Translation

  2026-09-28

  GW 6471 provides a controllable way to interrogate PPARα-dependent transcription across cellular metabolism research, lipid homeostasis studies, and environmental toxicology. This thought-leadership article connects the compound’s co-repressor-based mechanism with findings from a PFHxS zebrafish study and outlines a translational workflow that separates pathway association from causal involvement.

• Flumequine Workflows for Topoisomerase II Research

  2026-09-28

  Use Flumequine to connect topoisomerase II inhibition with cell-growth and cell-death measurements, rather than treating a single viability score as the whole drug response. This practical workflow pairs concentration- and time-resolved testing with handling guidance and assay-specific troubleshooting.

• SNAI1 Drives EMT and Stemness in Thymic Tumors

  2026-09-27

  A 2024 study identifies SNAI1 as a regulator of epithelial–mesenchymal transition and cancer stem cell-like traits in thymic epithelial tumors, linking its transcriptional activity to PIK3R2 and phosphorylated EphA2. Multi-omics and functional experiments support this pathway as a candidate mechanism of tumor progression, while leaving its therapeutic relevance for future validation.

• Hydroxytyrosol in Cardiovascular Mechanism Research

  2026-09-26

  Explore how Hydroxytyrosol can help distinguish redox, inflammatory, and cholesterol-efflux responses in cardiovascular research. This article examines key findings from a recent olive-oil polyphenol study and translates them into evidence-aware experimental decisions.

• JC-1 Mitochondrial Membrane Potential Assay Guide

  2026-09-25

  Connect mitochondrial depolarization measurements to studies of cancer-cell responses and immunomodulatory compounds with a ratiometric JC-1 workflow. Learn how to use CCCP controls, plan a practical pilot, and interpret results without treating membrane potential as a stand-alone measure of cell death.

• Neuromedin S (rat): Practical Assay Guidance

  2026-09-25

  Neuromedin S (rat) provides a defined peptide ligand for controlled studies of neuromedin U receptor signaling, with product-specific information on molecular weight, solubility, and storage. Use it for research assay development with vehicle and handling controls; the supplied information does not establish clinical use, in vivo dosing, or a validated assay concentration.

8098 records 3/540 page Previous Next 12345 下5页 Last page